R&D channel feed

Al­con touts PhI­II win for dry eye drug, plans mid-2024 FDA fil­ing

Last year

Blue­print to pull Gavre­to in cer­tain mar­kets, shelve EGFR pro­grams as it fo­cus­es on Ay­vak­it launch

Last year

Jen­nifer Doud­na, Fy­o­dor Urnov want to stream­line gene edit­ing stud­ies with Dana­her's help

Last year
Cell/Gene Tx

#JPM24 quick hits: A 'great year for M&A'; an op­ti­mistic Sarep­ta; Pfiz­er's CEO + more

Last year
Deals
Pharma

Pfiz­er CEO says it's back to ba­sics af­ter painful 2023 for in­vestors: #JPM24

Last year
Pharma

Ex­elix­is cuts 175 staffers to pri­or­i­tize late-stage drug de­vel­op­ment   

Last year
People

Bay­er’s $425M non-hor­mon­al ther­a­py for menopause symp­toms clears first PhI­II test

Last year

Af­fimed cuts up to 50% of em­ploy­ees to sup­port clin­i­cal projects, CEO de­parts

Last year
People

No­var­tis li­cens­es two car­dio­vas­cu­lar RNAi drugs from Chi­nese biotech for $185M up­front

Last year
Deals

Ver­tex paus­es di­a­betes islet cell ther­a­py study af­ter two pa­tient deaths it says are un­re­lat­ed to drug

Last year
Cell/Gene Tx

'If you could have the next Prozac, that’s in­tox­i­cat­ing': Sage’s post­par­tum de­pres­sion tri­umph and the fail­ure that fol­lowed

Last year
Pharma
In Focus

Mer­ck CEO in­di­cates in­ter­est in GLP-1 com­bi­na­tion ther­a­pies, may pur­sue deals

Last year
Deals

AlloVir lays off 95% of staffers af­ter shut­ter­ing PhI­II an­tivi­ral cell ther­a­py tri­als 

Last year
People

In­tel­lia Ther­a­peu­tics cuts 15% of work­force, ex­tends cash run­way in­to mid-2026

Last year
People

Ap­plied Ther­a­peu­tics on part­ner­ship hunt as it seeks path for­ward af­ter PhI­II di­a­bet­ic car­diomy­opa­thy fail

Last year

Al­lo­gene Ther­a­peu­tics plans re­struc­tur­ing as it swaps out PhII CAR-T tri­al plans to leapfrog ri­vals

Last year
Cell/Gene Tx

Claris rais­es $57M in Se­ries A as it awaits key tri­al read­out on eye drug

Last year
Financing
Startups

4BIO pulls De­vel­op­ment Bank of Japan to dip its toes in­to UK life sci­ence by back­ing lat­est fund

Last year
Financing
Deals

Ex­clu­sive: Roger Perl­mut­ter on the biggest prob­lem in Big Phar­ma, leav­ing Mer­ck, and build­ing Eikon

Last year
People
Startups

Lyn­dra’s long-act­ing risperi­done for­mu­la­tion hits PhI­II schiz­o­phre­nia tri­al end­points

Last year

Bay­er and AskBio re­veal ear­ly safe­ty da­ta for Parkin­son's gene ther­a­py, plot PhII study

Last year
Cell/Gene Tx

Kymera dou­bles down on pro­tein de­graders for im­munol­o­gy, chas­ing Dupix­ent and So­tyk­tu

Last year

Agios’ oral drug se­cures PhI­II suc­cess in trans­fu­sion-in­de­pen­dent tha­lassemia pa­tients

Last year

Roger Perl­mut­ter lights up the bi­o­log­i­cal dark, build­ing a new phar­ma force in Eikon and its su­per­pow­ered mi­cro­scopes

Last year
Startups
In Focus
First page Previous page 55565758596061 Next page Last page
A service from the Financial Times